Aoxing Pharma Commences Production of Tilidine Hydrochloride Tablets

FOSTER CITY, CA / ACCESSWIRE / June 30, 2016 / Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) (“Aoxing Pharma”), a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, today announced that it has started commercial production of Tilidine Hydrochloride tablets, a narcotic drug product. This is a significant milestone for the Company.

“The start of production of Tilidine tablet suggests that Aoxing’s capability in research and development has been recognized by the CFDA (China Food and Drug Administration),” said Mr. Zhenjiang Yue, Chairman and CEO of Aoxing Pharma. “We believe that the new products in our R&D programs, including other narcotic drugs, addiction treatment, weight loss treatment, and mental health-related pharmaceutical drugs, should become drivers for growth in the future. These achievements are the results of the hard work of our management team and all of our employees. We appreciate both the strong support and patience of our shareholders.”

About Aoxing Pharmaceutical Company, Inc.

Aoxing Pharmaceutical Company, Inc. is a US incorporated specialty pharmaceutical company with its operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. Headquartered in Shijiazhuang City, outside Beijing, Aoxing Pharma has one of the most advanced manufacturing facilities in China for highly regulated narcotic medicines.

Safe Harbor Statement from Aoxing Pharmaceutical Company, Inc.

Certain statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. All forward-looking statements included herein are based upon information available to the Company as of the date hereof and, except as is expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. To the extent that any statements made here are not historical, these statements are essentially forward-looking. Undue reliance should not be placed on forward-looking information. The economic, competitive, governmental, technological and other risk factors identified in the Company’s filings with the Securities and Exchange Commission, specifically, Item 1A, “Risk Factors,” in the Form 10-K for the year ended June 30, 2014, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

CONTACT:

Aoxing Pharmaceutical Company:
646-367-1747
investor.relations@aoxingpharma.com

SOURCE: Aoxing Pharmaceutical Company, Inc.

ReleaseID: 441847